Detail of "1609-66-1"

Reference

Pharmacogenomics as Molecular Autopsy for Forensic Toxicology: Genotyping Cytochrome P450 3A4*1B and 3A5*3 for 25 Fentanyl Cases

Pharmacogenomics as Molecular Autopsy for Forensic Toxicology: Genotyping Cytochrome P450 3A4*1B and 3A5*3 for 25 Fentanyl Cases. Jin, Ming; Gock, Susan B.; Jannetto, Paul J.; Jentzen, Jeffrey M.; Wong, Steven H. (Department of Pathology, Milwaukee County Medical Examiner's Office, Medical College of Wisconsin, Milwaukee, WI, USA). Journal of Analytical Toxicology, 29(7), 590-598 (English) 2005 Preston Publications. CODEN: JATOD3. ISSN: 0146-4760. DOCUMENT TYPE: Journal CA Section: 4 (Toxicology) Section cross-reference(s): 1, 3 Pharmacogenomics, the study on genetic contributions to drug action, may help in certifying fentanyl toxicity. Fentanyl is used clin. as an adjunct to surgical anesthesia and for chronic pain management. Its toxicity may be partially due to cytochrome P 450 (CYP) 3A4*1B and 3A5*3 variant alleles, resulting in variable fentanyl metab. In this study, the authors examd. 25 fentanyl-related deaths (22 Caucasians, 1 African-American, and 2 Native-Americans) from the Milwaukee County Medical Examiner's Office and referral cases. Fentanyl and norfentanyl in postmortem blood samples were analyzed by RIA and liq. chromatog.-mass spectrometry-mass spectrometry. The samples were then genotyped for CYP3A4*1B and 3A5*3 using Pyrosequencing.Several substances with their cas registry numbers 1609-66-1 and 329736-03-0 may be metioned in this study. Genotyping showed: 1CYP3A4*1B homozygous and CYP3A5*3 heterozygous, 1 compd. CYP3A4*1B and CYP3A5*3 heterozygous, 22 CYP3A4*1B wild type and CYP3A5*3 homozygous, and 1CYP3A5*3 and CYP3A4*1B wild type. CYP variant allelic frequencies of the 25 cases were 6% for CYP3A4*1B and 92% for CYP3A5*3, compared with normal Caucasian CYP3A4*1B, 3-8%, and CYP3A5*3, 85-95%. The mean fentanyl concn. and metabolic ratio of fentanyl to norfentanyl of the 2 cases with CYP3A4*1B and CYP3A5*3 variants were 12.8 and1.4 mg/L, resp., lower than those of 22 cases with wild type CYP3A4*1B and CYP3A5*3 homozygous variants, 16.7 and7.3 mg/L, resp. The postmortem/in vivo data provided the first scientific evidence that CYP3A5 is involved in the fentanyl metab., and homozygous CYP3A5 *3 causes impaired metab. of fentanyl, and genotyping CYP3A4*1B and 3A5*3 variants may help to certify the fentanyl toxicity. (c) 2005 Preston Publications. .

Analysis of fentanyl and norfentanyl in human plasma by liquid chromatography-tandem mass spectrometry using electrospray ionization

Analysis of fentanyl and norfentanyl in human plasma by liquid chromatography-tandem mass spectrometry using electrospray ionization. Day, J.; Slawson, M.; Lugo, R. A.; Wilkins, D. 437-38-7 and 1609-66-1 are also occured in this study. (Center for Human Toxicology, University of Utah, Salt Lake City, UT 84112, USA). Journal of Analytical Toxicology, 27(7), 513-516 (English) 2003 Preston Publications. CODEN: JATOD3. ISSN: 0146-4760. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) This report describes a sensitive and specific HPLC-electrospray ionization-tandem mass spectrometry (MS-MS) method for the detection of subnanogram concns. of fentanyl and its metabolite norfentanyl in human plasma. The assay was based on a liq.-liq. extn. of 0.5 mL of human plasma, with a lower limit of quantitation (LLOQ) of 0.05 ng/mL. Sample exts. were analyzed using a ThermoQuest TSQ MS-MS interfaced with a Hewlett-Packard series 1100 HPLC and a Phenomenex (30 ′ 2.00-mm, 5 m Luna C18(2)) column. The intra-assay precision and accuracy ranged from 2.1 to 12.5% for both analytes at concns. of 0.1, 0.5, 1.0, and 10 ng/mL. The interassay accuracy and precision ranged from 7.34 to 10.95%. (c) 2003 Preston Publications. .